Lemtrada Injection, Solution, Concentrate
Product Images NDC 58468-0200

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Lemtrada (NDC 58468-0200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genzyme Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Lemtrada 01)

A line graph comparing the percentage of patients with confirmed disability progression over 24 months between LEMTRADA (alemtuzumab) and interferon beta-1a treatment groups. The vertical axis shows percentage of patients, and the horizontal axis represents follow-up months. The LEMTRADA group shows a consistently lower percentage compared to interferon beta-1a, with annotated p-value 0.0084. Patient numbers at risk are indicated below the time axis for both groups.*

FDA Label Image

Principal Display Panel (12 mg/1.2 mL Vial Carton)

Packaging label for LEMTRADA (alemtuzumab) injection 12 mg/1.2 mL (10 mg/mL) concentrate for intravenous infusion. The carton includes storage instructions (refrigerate 2°C to 8°C), contents (single-dose vial), and manufacturer details (Genzyme Corporation, Cambridge, MA). It states dilution before infusion and single-dose vial usage with discard of unused portion. Bar code and serialization area are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.